Investing Where Quality Meets Potential

Coyote X is a private investment company focused on real estate, sports, entertainment, consumer brands, and select small companies. We source opportunities with durability and upside, structure conservatively, and execute with discretion to deliver outcomes that compound over time.

Start a Conversation

Investment Thesis

Quality Over Scale

We focus on opportunities in real estate, sports, entertainment, consumer brands, and private companies where scarcity, durability, and asymmetric upside exist. Scale matters less than quality and long-term resilience.

Disciplined Structuring

Every investment is grounded in conservative leverage, aligned incentives, and tax-efficient strategies. Whether acquiring an asset or backing an operating company, structure drives outcomes.

Operational Edge

We create value through hands-on execution — from leasing and repositioning to brand growth and operational efficiency. Our network advantage allows us to move quietly, with speed and precision.

Meet Aman Ahmed

Prior to Coyote X, Aman began his career at Nexus Pharmaceuticals, LLC in 2017, where he currently serves on the Board of Directors. As the Director of International Sales, he oversees the International Business Development, managing the company’s portfolio of products across multiple global regions.

With over seven years of experience, Aman has developed expertise in sales operations, navigating DEA and FDA regulations, inside sales, and portfolio management across various therapeutic lines. At Nexus, he was paramount in the strategic expansion of the Pleasant Prairie manufacturing facility and subsequent divestiture to Eli Lilly. His investment interests span healthcare, sustainability, and entertainment. Aman holds a Bachelor of Science degree in Healthcare Management and Policy from Indiana University. He is currently Principal Investor at Goldfinch Capital Partners.

With over seven years of experience, Aman has developed expertise in sales operations, navigating DEA and FDA regulations, inside sales, and portfolio management across various therapeutic lines. At Nexus, he was paramount in the strategic expansion of the Pleasant Prairie manufacturing facility and subsequent divestiture to Eli Lilly.
His investment interests span healthcare, sustainability, and entertainment. Aman holds a Bachelor of Science degree in Healthcare Management and Policy from Indiana University. He is currently Principal Investor at Goldfinch Capital Partners.